Cytokinetics Inc’s filing revealed that its Director B LYNNE PARSHALL acquired Company’s shares for reported $0.29 million on Aug 26 ’24. In the deal valued at $57.26 per share,5,000 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, PARSHALL B LYNNE sold 5,000 shares, generating $286,300 in total proceeds. Upon selling the shares at $57.26, the Director now owns 20,600 shares.
Before that, Malik Fady Ibraham sold 7,300 shares. Cytokinetics Inc shares valued at $410,638 were divested by the EVP Research & Development at a price of $56.25 per share. As a result of the transaction, Malik Fady Ibraham now holds 125,004 shares, worth roughly $7.14 million.
Goldman downgraded its Cytokinetics Inc [CYTK] rating to a Neutral from a a Buy in a research note published on August 13, 2024; the price target was decreased to $60 from $85. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Neutral”. Morgan Stanley also remained covering CYTK and has decreased its forecast on January 05, 2024 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Goldman started covering the stock on November 09, 2023. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Friday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -0.54% to $57.08. Over the last five days, the stock has lost -0.42%. Cytokinetics Inc shares have fallen nearly -31.63% since the year began. Nevertheless, the stocks have risen 62.07% over the past one year. While a 52-week high of $110.25 was reached on 01/08/24, a 52-week low of $25.98 was recorded on 05/28/24. SMA at 50 days reached $56.01, while 200 days put it at $61.33.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 56.24, which if violated will result in even more drops to 55.41. On the upside, there is a resistance level at 57.95. A further resistance level may holdings at 58.82. The Relative Strength Index (RSI) on the 14-day chart is 53.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.76%. Stochastics %K at 65.47% indicates the stock is a holding.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2024-08-15, growing by 1.17 million shares to a total of 18.63 million shares. Yahoo Finance data shows the prior-month short interest on 2024-07-15 was 17.46 million shares. There was a rise of 6.28%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 07, 2023 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $66 price target.
